NNVC (NanoViricides Inc.) Market Value to Book Value Ratio

Official company branding of nanoviricides.com (NNVC)

NanoViricides, Inc. (NNVC) develops advanced antiviral agents using proprietary nanotechnologies to disrupt pathogen structures while strictly adhering to environmental bio-waste disposal regulations. The market value dynamics of the asset, which currently stands at 3.84, are illustrated below. NanoViricides, Inc. (NNVC) is building a defense system by integrating "smart traps" into influenza and herpes medications to physically eliminate infections.

NNVC nanoviricides.com: Market Value to Book Value in the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for NanoViricides, Inc. (NNVC)

- price and consensus price forecast:
Stock Price nanoviricides.com|NNVC - Consensus Target
- market capitalization data:
Market Value NanoViricides Corp|NNVC - Full Business Value
- book capitalization data:
Book Value per Share NanoViricides|NNVC - Accounting Value of Company|Market Capitalization to Book Value Ratio nanoviricides.com|NNVC - Company Total Assets
- debt and liquidity data:
Debt to Equity NanoViricides, Inc.|NNVC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity nanoviricides.com|NNVC - Company Total Debt|Debts to Book Capitalization NanoViricides Corp
Initial company analysis:NanoViricides Inc. - NNVC
Original product of nanoviricides.com

This indicator mathematically captures the sensitivity of market expectations to actual capital volume. It compares the current share price with the book value of net assets, filtering out speculative noise. For NanoViricides, Inc. (NNVC), this calculation confirms the value of its own manufacturing facility in Connecticut. Analyzing the price-to-book ratio allows for the determination of the premium paid for production capacities. The dynamics of this metric reveal the fair value of the business.

Main competitors

GILD (Gilead Sciences, Inc.) - Market Capitalization to Book Value Ratio|CDTX (Cidara Therapeutics) - Market Cap to Net Assets Ratio|Market Value to Book Value Ratio Novavax NVAX|Market Capitalization to Net Assets CureVac NV|Valneva Pharma (VALN) - Market Capitalization to Book Value Ratio|Market Value to Book Value Vir Corp (VIR)|Market Capitalization to Book Value Ratio SIGA (SIGA Technologies, Inc.)|emergentbiosolutions.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Atea Pharmaceuticals, Inc. (AVIR)|IVVD: Market Value to Book Value|ENTA (Enanta) - Market Value to Book Value Ratio|Inovio Pharma (INO) - Market Cap to Net Assets Ratio|HLVX (HilleVax, Inc.) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio kalaristx.com (KLRS)|Dyadic International (DYAI) - Market Cap to Net Assets Ratio|Market Value to Book Value Talphera Inc TLPH|Market Cap to Net Assets Ratio Cocrystal COCP|Market Value to Book Value Ratio Traws Pharma Inc TRAW|Market Capitalization to Book Value Ratio DWTX (Virios Therapeutics)|QLGN: Market Capitalization to Book Value|Market Value to Book Value Ratio allovir.com ALVR|Market Value to Book Value VBI Vaccines|VIRI (Virios Therapeutics Inc.) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio VXRT